Exelixis Inc Deferred Income Tax Assets, Net
Exelixis Inc (EXEL) had Deferred Income Tax Assets, Net of $294.20 million as of 2026-07-03, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:DeferredIncomeTaxAssetsNet · last filed 2026-08-05
- 2026-07-03: Deferred Income Tax Assets, Net $294.20M.
- 2026-04-03: Deferred Income Tax Assets, Net $293.73M.
- 2026-01-02: Deferred Income Tax Assets, Net $292.58M.
- 2025-10-03: Deferred Income Tax Assets, Net $418.58M.
| Period end | Deferred Income Tax Assets, Net |
|---|---|
| 2026-07-03 | $294.20M 10-Q · filed 2026-08-05 |
| 2026-04-03 | $293.73M 10-Q · filed 2026-05-05 |
| 2026-01-02 | $292.58M 10-Q · filed 2026-08-05 |
| 2025-10-03 | $418.58M 10-Q · filed 2025-11-04 |
| 2025-07-04 | $419.24M 10-Q · filed 2025-07-28 |
| 2025-04-04 | $419.05M 10-Q · filed 2025-05-13 |
| 2025-01-03 | $420.03M 10-K · filed 2026-02-10 |
| 2024-09-27 | $358.87M 10-Q · filed 2024-10-29 |
| 2024-06-28 | $361.56M 10-Q · filed 2024-08-06 |
| 2024-03-29 | $361.58M 10-Q · filed 2024-04-30 |
| 2023-12-29 | $361.14M 10-K · filed 2025-02-11 |
| 2023-09-29 | $230.99M 10-Q · filed 2023-11-01 |
| 2023-06-30 | $231.12M 10-Q · filed 2023-08-01 |
| 2023-03-31 | $229.60M 10-Q · filed 2023-05-09 |
| 2022-12-30 | $231.11M 10-K · filed 2024-02-06 |
| 2022-09-30 | $116.42M 10-Q · filed 2022-11-01 |
| 2022-07-01 | $113.96M 10-Q · filed 2022-08-09 |
| 2022-04-01 | $98.00M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $111.66M 10-K · filed 2023-02-07 |
| 2021-10-01 | $125.30M 10-Q · filed 2021-11-02 |
| 2021-07-02 | $134.67M 10-Q · filed 2021-08-05 |
| 2021-04-02 | $160.60M 10-Q · filed 2021-05-06 |
| 2021-01-01 | $156.71M 10-K · filed 2022-02-18 |
| 2020-10-02 | $155.68M 10-Q · filed 2020-11-05 |
| 2020-07-03 | $148.24M 10-Q · filed 2020-08-06 |
| 2020-04-03 | $163.19M 10-Q · filed 2020-05-05 |
| 2020-01-03 | $172.37M 10-K · filed 2021-02-11 |
| 2019-09-27 | $186.84M 10-Q · filed 2019-10-30 |
| 2019-06-28 | $210.24M 10-Q · filed 2019-07-31 |
| 2019-03-29 | $243.72M 10-Q · filed 2019-05-01 |
| 2018-12-28 | $244.11M 10-K · filed 2020-02-25 |
| 2017-12-29 | $0.00 10-K · filed 2019-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |